{"id":"labetalol-intravenous","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL429","moleculeType":"Small molecule","molecularWeight":"328.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Labetalol acts as a non-selective beta-blocker with concurrent alpha-1 adrenergic blocking activity, resulting in vasodilation and reduced cardiac output. The intravenous formulation provides rapid onset of action, making it suitable for acute hypertensive episodes. The dual mechanism produces effective blood pressure reduction with a favorable hemodynamic profile compared to pure beta-blockers.","oneSentence":"Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking sympathetic nervous system signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:21.334Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute hypertension"},{"name":"Hypertensive emergency"},{"name":"Perioperative hypertension"}]},"trialDetails":[{"nctId":"NCT07364201","phase":"NA","title":"A Comparison of Nicardipine and Labetalol for Blood Pressure Control in Intensive Care Patients After Hemorrhagic Stroke Brain Surgery","status":"COMPLETED","sponsor":"Universitas Sumatera Utara","startDate":"2025-11-14","conditions":"Hemorrhagic Strokes, Postoperative Hypertension, Hemodynamic Instability","enrollment":30},{"nctId":"NCT07277283","phase":"PHASE4","title":"Nicardipine vs. Labetalol","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2025-02-01","conditions":"Acute Ischemic Stroke, Hypertensive Crisis","enrollment":34},{"nctId":"NCT07192081","phase":"NA","title":"Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy","status":"RECRUITING","sponsor":"Dr. Waseem Ullah","startDate":"2025-06-05","conditions":"Intubation, Anesthesia, Laparoscopic Cholecystectomy","enrollment":116},{"nctId":"NCT05139238","phase":"PHASE4","title":"Postpartum Hypertension Study","status":"RECRUITING","sponsor":"Columbia University","startDate":"2022-07-04","conditions":"Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Pregnancy-Induced Hypertension in Postpartum","enrollment":104},{"nctId":"NCT06360601","phase":"PHASE1, PHASE2","title":"Intravenous Labetalol Versus Hydralazine in Preeclampsia","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-04-01","conditions":"Preeclampsia Severe","enrollment":40},{"nctId":"NCT02281838","phase":"PHASE2","title":"The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2011-08-01","conditions":"Intracerebral Hemorrhage","enrollment":142},{"nctId":"NCT06385600","phase":"NA","title":"Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-05-20","conditions":"Severe Pre-eclampsia","enrollment":200},{"nctId":"NCT06265415","phase":"NA","title":"Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2024-03-30","conditions":"Severe Preeclampsia","enrollment":60},{"nctId":"NCT04116112","phase":"PHASE2","title":"Blood Pressure After Endovascular Stroke Therapy-II","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2020-01-17","conditions":"Acute Stroke, Endovascular Thrombectomy","enrollment":120},{"nctId":"NCT04892511","phase":"PHASE4","title":"Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-06-01","conditions":"Acute Ischemic Stroke","enrollment":814},{"nctId":"NCT04539379","phase":"NA","title":"Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-10-01","conditions":"Magnesium Sulfate, Labetalol","enrollment":60},{"nctId":"NCT02135315","phase":"NA","title":"Intensive Arterial Pressure Control in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2014-03","conditions":"Acute Coronary Syndrome","enrollment":1500},{"nctId":"NCT05310929","phase":"NA","title":"Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-08-28","conditions":"Severe Pre-eclampsia","enrollment":200},{"nctId":"NCT03506724","phase":"PHASE4","title":"Response to Anti-hypertensives in Pregnant and Postpartum Patients","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2017-09-11","conditions":"Hypertension in Pregnancy, Preeclampsia","enrollment":109},{"nctId":"NCT02997800","phase":"PHASE2","title":"The Effect of Intraoperative Labetalol on Time to Discharge","status":"COMPLETED","sponsor":"Dr. Robert Tanzola","startDate":"2012-11","conditions":"Bloodpressure, Heart Rate","enrollment":172},{"nctId":"NCT03761888","phase":"","title":"Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia","status":"UNKNOWN","sponsor":"Hopital Antoine Beclere","startDate":"2018-11-29","conditions":"Preeclampsia Severe","enrollment":60},{"nctId":"NCT02050529","phase":"PHASE2","title":"Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2012-10","conditions":"Hypertension, Pregnancy Induced, Hydralazine Adverse Reaction, Pre-eclampsia","enrollment":190},{"nctId":"NCT02327793","phase":"PHASE2","title":"Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-06","conditions":"Stroke, Acute","enrollment":65},{"nctId":"NCT01176565","phase":"PHASE3","title":"Antihypertensive Treatment of Acute Cerebral Hemorrhage-II","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2011-05-15","conditions":"Intracerebral Hemorrhage","enrollment":1000},{"nctId":"NCT01942356","phase":"NA","title":"Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2013-09","conditions":"Acute Cholecystitis, Chronic Cholecystitis","enrollment":4},{"nctId":"NCT00765648","phase":"PHASE4","title":"Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2008-10","conditions":"Hypertensive Urgency","enrollment":226},{"nctId":"NCT00716079","phase":"NA","title":"The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2008-09","conditions":"Intracerebral Hemorrhage, Stroke, Hypertension","enrollment":2839},{"nctId":"NCT00963976","phase":"PHASE2","title":"Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2007-01","conditions":"Intracerebral Hemorrhage","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":489,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"labetalol intravenous","genericName":"labetalol intravenous","companyName":"Haseki Training and Research Hospital","companyId":"haseki-training-and-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking sympathetic nervous system signaling. Used for Acute hypertension, Hypertensive emergency, Perioperative hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}